Global Health Progress

Read Global Health Progress’ fact sheet summarizing Russia’s plan for the biotechnology sector will improve access to drugs, increase pharmaceutical R&D investment and drive economic growth in the region

An eminent international panel of judges has selected Eli Lilly and Company (NYSE: LLY) to receive a World Business and Development Award for demonstrating what can be achieved through successful partnerships in the battle against multidrug-resistant tuberculosis (MDR-TB).

Learn how Brazil’s investment in research and development promotes innovation, contributes to the country’s economic growth, and expands access to healthcare

New vaccines against the pneumococcal bacteria and rotavirus could save more than one million children’s lives each year, but a USD 4 billion gap in funding threatens these and other immunisation programmes, a report published jointly today by the International Federation of Red Cross and Red Crescent Societies (IFRC) and the GAVI Alliance, said.

Read why Global Health Progress believes the growth of Turkey’s biotechnology sector attracts and boosts research and development expenditures and improves access to medicine.

Learn why Global Health Progress believes failing to protect intellectual property rights will only worsen Africa’s healthcare crisis

Johnson & Johnson today announced the launch of Every Mother, Every Child, a comprehensive, five-year, private-sector effort to improve the health of women and children in developing countries. The initiative supports the United Nations’ April 2010 call for a renewed effort to achieve the Millennium Development Goals (MDGs) of reducing mortality in women and children by 2015.

Discover why Global Health Progress supports drug development to combat “untouchable” diseases.